Immuno-based Profiling of knEe OA Patients to Predict reSponse to Regenerative Treatment - Trial NCT06384040
Access comprehensive clinical trial information for NCT06384040 through Pure Global AI's free database. This phase not specified trial is sponsored by Istituto Clinico Humanitas and is currently Recruiting. The study focuses on Osteoarthritis, Knee. Target enrollment is 105 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Istituto Clinico Humanitas
Timeline & Enrollment
N/A
Nov 01, 2021
Oct 30, 2024
Primary Outcome
knee OA patients focusing on changes in Wnt and IL1-ß signalling and PTX3 expression
Summary
Osteoarthritis (OA) is a highly prevalent degenerative musculoskeletal disease and a major
 cause of chronic disability worldwide. Its multifactorial origin contributes to determine the
 heterogeneous phenotypes and one unmet need is the lack of biomarkers to predict the
 individual response. Platelet-rich-plasma (PRP) injection is a minimally invasive autologous
 blood-derived approach for which we plan to define specific knee profiles predictive of
 response. We will take advantage of a unique multidisciplinary approach aimed at analysing
 clinics, imaging, and biomarkers of associated with clinical response. We will focus on
 inflammatory (Wnt system, IL1 pathway, PTX3) and antioxidant (primarily, DPP3/Keap1/Nrf2)
 pathways. We foresee that our results will allow a better allocation of immunomodulatory and
 regenerative therapies for a personalized approach in knee OA thus maximising the
 effectiveness of the healthcare allocation.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06384040
Non-Device Trial